Genmab - ADR Aktie News

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumuma...

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, impro...

Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrat...

Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Genmab is transitioning from a royalty-driven licensor to an innovation powerhouse with a robust, proprietary pipeline. GMAB delivered 21% revenue growth and 52% operating profit growth, supported by $3.4B in cash and strong operating leverage. Epkinly and Rina-S, with positive clinical data and full or majority ownership, underpin GMAB's multi-billion dollar peak sales potential.

Media Release COPENHAGEN, Denmark; January 07, 2026 Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB ) a nnounced today a partnership with Anthropic to advance and enhance the company's r esearch and d evelopment (R&D) processes through the adoption of cutting-...